Publications
Publications
Show Results For
- All HBS Web
(1,320)
- Faculty Publications (214)
- December 2022 (Revised February 2023)
- Case
Daniel Defense: Responding to the Shooting at the Robb Elementary School in Uvalde, TX
By: Benjamin C. Esty and Daniel Fisher
At 11:33am on May 24, 2022, an 18-year-old man from Uvalde, Texas walked into the Robb Elementary School carrying a semi-automatic "AR-15-style” rifle manufactured by Daniel Defense and killed 19 children and two adults. Three days later, Representative Carolyn Maloney... View Details
Keywords: Gun Violence; Gun Policy; Second Amendment; Legal Liability; Government Legislation; Marketing Strategy; Business or Company Management; Product Marketing; Ethics; Corporate Accountability; Corporate Social Responsibility and Impact; Moral Sensibility; Crime and Corruption; Governing Rules, Regulations, and Reforms; Manufacturing Industry; Advertising Industry; United States
- 2023
- Working Paper
Nailing Prediction: Experimental Evidence on the Value of Tools in Predictive Model Development
By: Daniel Yue, Paul Hamilton and Iavor Bojinov
Predictive model development is understudied despite its centrality in modern artificial
intelligence and machine learning business applications. Although prior discussions
highlight advances in methods (along the dimensions of data, computing power, and
algorithms)... View Details
Keywords: Analytics and Data Science
- December 2022
- Article
Fostering Perceptions of Authenticity via Sensitive Self-Disclosure
By: Li Jiang, Leslie K. John, Reihane Boghrati and Maryam Kouchaki
Leaders’ perceived authenticity—the sense that leaders are acting in accordance with their “true self”—is associated with positive outcomes for both employees and organizations alike. How might leaders foster this impression? We show that sensitive self-disclosure, in... View Details
- December 2022
- Article
Initial Coin Offering (ICO) Success and Post-ICO Performance
By: Evgeny Lyandres, Berardino Palazzo and Daniel Rabetti
We compile a comprehensive data set of initial coin offerings (ICOs) from 19 data sources including 11 ICO aggregators. We alleviate severe limitations of available ICO data by performing the first systematic analysis of ICO data quality. We use our data set to study... View Details
- November 2022 (Revised December 2024)
- Case
Hugging Face (A): Serving AI on a Platform
By: Shane Greenstein, Daniel Yue, Sarah Gulick and Kerry Herman
It is fall 2022, and open-source AI model company Hugging Face is considering its three areas of priorities: platform development, supporting the open-source community, and pursuing cutting-edge scientific research. As it expands services for enterprise clients, which... View Details
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
- August, 2022
- Article
Billing and Insurance-Related Administrative Costs: A Cross-National Analysis
By: Barak D. Richman, Robert S. Kaplan, Japees Kohli, Dennis Purcell, Mahek Shah, Igna Bonfrer, Brian Golden, Rosemary Hannam, Will Mitchell, Daniel Cehic, Garry Crispin and Kevin A. Schulman
Billing and insurance-related costs are a significant source of wasteful health care spending in Organization for Economic Cooperation and Development nations, but these administrative burdens vary across national systems. We executed a microlevel accounting of these... View Details
- June 2022
- Article
Conservatism Gets Funded? A Field Experiment on the Role of Negative Information in Novel Project Evaluation
By: Jacqueline N. Lane, Misha Teplitskiy, Gary Gray, Hardeep Ranu, Michael Menietti, Eva C. Guinan and Karim R. Lakhani
The evaluation and selection of novel projects lies at the heart of scientific and technological innovation, and yet there are persistent concerns about bias, such as conservatism. This paper investigates the role that the format of evaluation, specifically information... View Details
- May 2022 (Revised April 2024)
- Case
Third Point in 2020: Growth Is Where the Value Is?
By: Robin Greenwood, James Williams and Denise Han
In early May 2020, Daniel Loeb’s team at Third Point was evaluating a potential growth opportunity in the Walt Disney Company and whether investor activism might play a role. Battered by the effects of COVID-19, the company’s stock had initially tumbled to $86 and then... View Details
- May 2022
- Supplement
Third Point in 2020: Growth Is Where the Value Is? (B)
By: Robin Greenwood and Denise Han
In early May 2020, Daniel Loeb’s team at Third Point was evaluating a potential growth opportunity in the Walt Disney Company and whether investor activism might play a role. Battered by the effects of COVID-19, the company’s stock had initially tumbled to $86 and then... View Details
- May 2022 (Revised July 2022)
- Case
The Voice War Continues: Hey Google vs. Alexa vs. Siri in 2022
By: David B. Yoffie and Daniel Fisher
In 2022, after five years of pursuing a new "AI-first" strategy, Google had captured a sizeable share of the American and global markets for voice assistants. Google Assistant was used by hundreds of millions of users around the world, but Amazon retained the largest... View Details
- April 2022
- Case
NIO: A Chinese EV Company's Global Strategy
By: William C. Kirby, Shu Lin and Noah B. Truwit
Founded in November 2014 and based in Shanghai, NIO designed, jointly manufactured, and sold premium “smart” EVs. Its mission was to “shape a joyful lifestyle by offering high-performance smart electric vehicles and being the best user enterprise. At NIO Day 2021,... View Details
- 2022
- Working Paper
THEMIS: A Framework for Cost-Benefit Analysis of COVID-19 Non-Pharmaceutical Interventions
By: Dimitris Bertsimas, Michael Lingzhi Li and Saksham Soni
Since December 2019, the world has been ravaged by the COVID-19 pandemic, with over 150 million confirmed cases and 3 million confirmed deaths worldwide. To combat the spread of COVID-19, governments have issued unprecedented non-pharmaceutical interventions (NPIs),... View Details
Keywords: COVID-19; Health Pandemics; Policy; Framework; Cost vs Benefits; Outcome or Result; United States; Germany; Brazil; Singapore; Spain
- March 2022
- Article
Where to Locate COVID-19 Mass Vaccination Facilities?
By: Dimitris Bertsimas, Vassilis Digalakis Jr, Alexander Jacquillat, Michael Lingzhi Li and Alessandro Previero
The outbreak of COVID-19 led to a record-breaking race to develop a vaccine. However, the limited vaccine capacity creates another massive challenge: how to distribute vaccines to mitigate the near-end impact of the pandemic? In the United States in particular, the new... View Details
- 2022
- Article
Missing Novelty in Drug Development
By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to... View Details
- 2022
- Chapter
The Servicification of the U.S. Economy: The Role of Startups versus Incumbent Firms
By: Mercedes Delgado, J. Daniel Kim and Karen G. Mills
Over the last few decades, the U.S. economy has exhibited a significant shift from manufacturing towards services. This transition has been particularly prominent in an important subcategory of services industries that drives innovation and employs many high-wage... View Details
- January 2022 (Revised April 2025)
- Case
Steem Versus Hive: Testing Blockchain Governance
By: Shikhar Ghosh and Shweta Bagai
This case examines a pivotal governance conflict that occurred in 2020 when Justin Sun, founder of the TRON blockchain, acquired Steemit Inc., the company behind a popular social media platform operating on the Steem blockchain. Steem, launched in 2016 by Daniel... View Details
- December 2021 (Revised May 2025)
- Case
Bed Bath & Beyond: The New Strategy to Drive Shareholder Value
By: Benjamin C. Esty and Daniel W. Fisher
At one time, Bed Bath & Beyond was one of the most successful specialty retailers in the United States—its growth and profit margins far exceeded both peer retailers in the home goods market as well as many other discount retailers. But in 2014, its stock price peaked,... View Details
- Winter 2021
- Article
Can Staggered Boards Improve Value? Causal Evidence from Massachusetts
By: Robert Daines, Shelley Xin Li and Charles C.Y. Wang
We study the effect of staggered boards (SBs) using a quasi-experiment: a 1990 law that imposed an SB on all Massachusetts-incorporated firms. The law led to an increase in Tobin's Q, investment in CAPEX and R&D, patents, higher-quality patented innovations, and... View Details
- Article
Reliable Post hoc Explanations: Modeling Uncertainty in Explainability
By: Dylan Slack, Sophie Hilgard, Sameer Singh and Himabindu Lakkaraju
As black box explanations are increasingly being employed to establish model credibility in high stakes settings, it is important to ensure that these explanations are accurate and reliable. However, prior work demonstrates that explanations generated by... View Details